| Stephen A Klautky, MD | |
|
185 W Cedar St, Suite 100, Akron, OH 44307-2400 | |
| (330) 376-0500 | |
| (330) 376-9900 |
| Full Name | Stephen A Klautky |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 25 Years |
| Location | 185 W Cedar St, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356453450 | NPI | - | NPPES |
| 2682468 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 3588401 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Summa Health System | Akron, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summa Physicians Inc | 2961303532 | 640 |
News Archive
With over two-thirds of U.S. adults owning a smartphone, and the rise in miniaturized sensors and low-power body area networks that are used for remote health monitoring, mobile health is beginning to experience a boom.
Patients with stable coronary artery disease (CAD) had a lower need for urgent revascularisation when receiving fractional flow reserve (FFR)-guided PCI plus the best available medical therapy (MT) than when receiving MT alone. The results, from a final analysis of the FAME 2 trial, were presented today during a Hot Line session of ESC Congress 2012 in Munich.
Scientists at Rochester Institute of Technology and Dowling College are engaged in a similar game with higher stakes. Instead of cards, they are matching the protein to the job it performs in the human body. Their research could lead to drugs that target proteins and switch on or off specific functions associated with various diseases.
Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
› Verified 8 days ago
| Entity Name | Summa Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235167719 PECOS PAC ID: 2961303532 Enrollment ID: O20040116000295 |
News Archive
With over two-thirds of U.S. adults owning a smartphone, and the rise in miniaturized sensors and low-power body area networks that are used for remote health monitoring, mobile health is beginning to experience a boom.
Patients with stable coronary artery disease (CAD) had a lower need for urgent revascularisation when receiving fractional flow reserve (FFR)-guided PCI plus the best available medical therapy (MT) than when receiving MT alone. The results, from a final analysis of the FAME 2 trial, were presented today during a Hot Line session of ESC Congress 2012 in Munich.
Scientists at Rochester Institute of Technology and Dowling College are engaged in a similar game with higher stakes. Instead of cards, they are matching the protein to the job it performs in the human body. Their research could lead to drugs that target proteins and switch on or off specific functions associated with various diseases.
Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen A Klautky, MD 185 W Cedar St, Suite 100, Akron, OH 44307-2400 Ph: (330) 376-0500 | Stephen A Klautky, MD 185 W Cedar St, Suite 100, Akron, OH 44307-2400 Ph: (330) 376-0500 |
News Archive
With over two-thirds of U.S. adults owning a smartphone, and the rise in miniaturized sensors and low-power body area networks that are used for remote health monitoring, mobile health is beginning to experience a boom.
Patients with stable coronary artery disease (CAD) had a lower need for urgent revascularisation when receiving fractional flow reserve (FFR)-guided PCI plus the best available medical therapy (MT) than when receiving MT alone. The results, from a final analysis of the FAME 2 trial, were presented today during a Hot Line session of ESC Congress 2012 in Munich.
Scientists at Rochester Institute of Technology and Dowling College are engaged in a similar game with higher stakes. Instead of cards, they are matching the protein to the job it performs in the human body. Their research could lead to drugs that target proteins and switch on or off specific functions associated with various diseases.
Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
› Verified 8 days ago
Dr. Michael A Pelini, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St, Ste 300, Akron, OH 44304 Phone: 330-376-7000 Fax: 330-376-1066 | |
David P. Lang, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 4125 Medina Rd, #200c, Akron, OH 44333 Phone: 330-665-8031 Fax: 330-665-8360 | |
Ms. Tiffany Mccann, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3561 | |
Jonathan Buggey, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St Ste 300, Akron, OH 44304 Phone: 724-422-6808 | |
Shamsa Baaj, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Mira Rohit Patel, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 161 N Forge St Ste 198, Akron, OH 44304 Phone: 330-375-3039 | |
Richard J Streck, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, 5th Floor Ambulatory Care Center, Akron, OH 44307 Phone: 330-344-6015 Fax: 330-344-6820 |